U.S. recommends ‘pause’ for Johnson & Johnson COVID-19 vaccine over clot reports

U.S. federal distribution channels, including mass vaccination sites, will pause the use of the Johnson & Johnson shot, and states and other providers are expected to follow

April 13, 2021 05:11 pm | Updated 07:51 pm IST - WASHINGTON

More than 6.8 million doses of the J&J vaccine have been administered in the U.S. (Illustrative image)

More than 6.8 million doses of the J&J vaccine have been administered in the U.S. (Illustrative image)

The U.S. is recommending a “pause” in administration of the single-dose Johnson & Johnson COVID-19 vaccine to investigate reports of potentially dangerous blood clots.

In a joint statement on April 13, the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) said it was investigating clots in six women in the days after vaccination, in combination with reduced platelet counts. More than 6.8 million doses of the J&J vaccine have been administered in the U.S.

U.S. federal distribution channels, including mass vaccination sites, will pause the use of the J&J shot, and states and other providers are expected to follow.

CDC’s Advisory Committee on Immunisation Practices will meet on April 14 to discuss the cases and the FDA has also launched an investigation of the cases.

“Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution,” Dr. Anne Schuchat, Principal Deputy Director of the CDC and Dr. Peter Marks, director of the FDA’s Centre for Biologics Evaluation and Research said in a joint statement.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.